TOKYO (Bloomberg): Takeda Pharmaceutical Co is developing an experimental therapy for the novel coronavirus or Covid-19 with the goal of making it available in 9 to 18 months, Japan’s largest drugmaker said.
"We will do all that we can to address the novel coronavirus threat, ” Dr Rajeev Venkayya, president of Takeda’s vaccine business unit and head of the response team, said in a statement Wednesday (March 4).
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
